COMP <GO>
SRPT vs LLY // RETURN ON INVESTED CAPITAL (ROIC)
Sarepta Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: SRPT 1
— LLY 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: LLY
LAST: $19.23 (-0.47%) • MKT CAP: $2.03B
roic
-35.00%
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
roic
32.36%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRPT VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRPT | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 83.64% | +12.36 | SRPT | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -15.14% | 2.30% | -17.44 | LLY | /fcf-yield <GO> |
| Operating Margin | -37.50% | 40.21% | -77.71 | LLY | /operating-margins <GO> |
| Net Profit Margin | -38.30% | 31.90% | -70.20 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 4.30% | 45.51% | -41.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 9.29 | -9.09 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 9/9 | -5.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.2 | 66.6 | -15.39 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 26.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.03B | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRPT REV | LLY REV | SRPT GROSS % | LLY GROSS % | SRPT FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.86B | $65.18B | 98.0% | 83.0% | -$307.5M | $16.81B |
| FY 2024 | $1.79B | $45.04B | — | 81.3% | -$342.7M | $8.82B |
| FY 2023 | $1.14B | $34.12B | — | 79.3% | -$501.0M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRPT // BETA —
LLY // BETA 0.51